ShareValue scores for 0DPB.LSE: Valuation 50, Quality 64, Growth 50, Health 53.
0DPB.LSELSE
Bavarian Nordic A/S
£1.76
(-2.06%)
0DPB.LSELSE
Bavarian Nordic A/S
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.